A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by Fibroblast Growth Factor-2 in Human Cancer Cells

Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling

(2010) Edwin Chen et al.   CANCER CELL

Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation

(2010) Simone Radtke et al.   JOURNAL OF CELL SCIENCE

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo

(2009) O. E. Pardo et al.   CANCER RESEARCH

Signal Transducers and Activators of Transcription Mediate Fibroblast Growth Factor–Induced Vascular Endothelial Morphogenesis

(2009) Xinhai Yang et al.   CANCER RESEARCH

Integration of cytokine and heterologous receptor signaling pathways

(2009) Jelena S Bezbradica et al.   NATURE IMMUNOLOGY

Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance

(2008) O. Simma et al.   CANCER RESEARCH

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS

STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes

(2008) P. Krejci et al.   JOURNAL OF CELL SCIENCE

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE

Multiple kinases in the interferon-  response

(2008) D. Watling et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The JAK kinases: Not just another kinase drug discovery target

(2008) Andrew F. Wilks   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY